Saturday August 24, 2019 23:25

Heathcare Press Release : 12 Jun 2019

Oral semaglutide demonstrated cardiovascular safety in people with type 2 diabetes and established Heathcare—12 Jun 19

Novo Nordisk today announced that the PIONEER 6 trial achieved its primary endpoint by demonstrating non-inferiority of major adverse cardiovascular events (MACE) with oral semaglutide compared with placebo, both in addition to standard of care. The

Zeus Expands Portfolio with New Polyimide Family of Products Heathcare—12 Jun 19

Products Include PI Tubing, PI Coated Wire, PI Glide(TM) Tubing, and PI Glide(TM) Coated Wire Zeus Industrial Products, Inc. (Zeus), a leading polymer solutions provider and material science innovator, has announced the introduction of a new polyimide